Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CTMX

This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Will These 3 Pharma Stocks Leave Investors Triumphant in 2024?

The pharmaceutical industry is undergoing a transformative shift driven by the advent of personalized drugs, technological innovations, and growing usage. Against this backdrop, does the inclusion of pharma stocks CytomX Therapeutics (CTMX), Merck & Co (MRK), and Neurocrine Biosciences (NBIX) in your portfolio appear wise? Let’s find out….

StockNews.com

Bullish or Bearish: 3 Pharma Options

The pharmaceutical industry’s robust outlook is driven by high healthcare spending globally, consistent R&D efforts, and the rapid adoption of advanced digital technologies. So, let’s analyze if investors should adopt a bullish or bearish stance on pharma stocks such as Tilray Brands (TLRY), CytomX Therapeutics (CTMX), and Wave Life Sciences…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com

3 Pharma Stocks on the Rise - It's Time to Buy Now

The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological innovations. Hence, quality pharma stocks, CytomX Therapeutics (CTMX), Eton Pharmaceuticals (ETON), and GSK (GSK), might be solid investments now for potential…

StockNews.com

4 Downgraded Stocks to Stay Away From in July

With the increasing odds of the economy slipping into a recession due to the Fed’s aggressive interest rate hikes to reduce inflation, it could be difficult for fundamentally weak stocks to find support anytime soon. DiaMedica (DMAC), CytomX (CTMX), Meta Financial (CASH), and Live Oak (LOB) have recently been downgraded…

StockNews.com

CytomX Therapeutics: Q1 Earnings Insights

CytomX Therapeutics (NASDAQ:CTMX) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

CytomX Therapeutics: Q4 Earnings Insights

CytomX Therapeutics (NASDAQ:CTMX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Organisations

Medical Pharmaceuticals

Neurocrine Biosciences Inc

12 stories

Wave Life Sciences Ltd

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

321,249 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.